Article PDF
Références
Levy SB, (1992) The Antibiotic Paradox: How Miracle Drugs Are Destroying the Miracle. New York, Plenum, 279 pp.
Roberts JA, Taccone FS, Lipman J, (2016) Understanding PKPD. Intensive Care Med 42: 1797–1800
Zasowski EJ, Trinh TD, Claeys KC, Casapao AM, Sabagha N, Lagnf AM, Klinker KP, Davis SL, Rybak MJ, (2017) Multicenter observational study of Ceftaroline Fosamil for methicillinresistant Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother 61: pii: e02015–16
Castón JJ, De la Torre Á, Ruiz-Camps I, Sorlí ML, Torres V, Torre-Cisneros J, (2017) Salvage therapy with ceftolozanetazobactam for multidrug resistant P. aeruginosa infections. Antimicrob Agents Chemother 61: pii: e02136–16
Shields RK, Potoski BA, Haidar G, Hao B, Doi Y, Chen L, Press EG, Kreiswirth BN, Clancy CJ, Nguyen MH, (2016) Clinical outcomes, drug toxicity, and emergence of ceftazidimeavibactam resistance among patients treated for carbapenemresistant Enterobacteriaceae infections. Clin Infect Dis 63: 1615–1618
Temkin E, Torre-Cisneros J, Beovic B, Benito N, Giannella M, Gilarranz R, Jeremiah C, Loeches B, Machuca I, Jiménez-Martín MJ, Martínez JA, Mora-Rillo M, Navas E, Osthoff M, Pozo JC, Ramos Ramos JC, Rodriguez M, Sánchez-García M, Viale P, Wolff M, Carmeli Y, (2017) Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms. Antimicrob Agents Chemother 24: pii: e01964–16
Haidar G, Clancy CJ, Shields RK, Hao B, Cheng S, Nguyen MH, (2017) Mutations in blaKPC-3 that confer ceftazidime-avibactam resistance encode novel KPC-3 variants that function as extended-spectrum β-lactamases. Antimicrob Agents Chemother 21: pii: AAC.02534-16
Marshall S, Hujer AM, Rojas LJ, Papp-Wallace KM, Humphries RM, Spellberg B, Hujer KM, Marshall EK, Rudin SD, Perez F, Wilson BM, Wasserman RB, Chikowski L, Paterson DL, Vila AJ, van Duin D, Kreiswirth BN, Chambers HF, Fowler VG Jr, Jacobs MR, Pulse ME, Weiss WJ, Bonomo RA, (2017) Can ceftazidime/avibactam and aztreonam overcome β-lactam resistance conferred by metallo-β-lactamases in Enterobacteriaceae? Antimicrob Agents Chemother [in press]
Tzouvelekis LS, Markogiannakis A, Piperaki E, Souli M, Daikos ML, (2014) Treating infections caused by carbapenemaseproducing Enterobacteriaceae. Clin Microbiol Infect 20: 862–872
Livermore D, Mushtaq S, Woodford N, (2016) In vitro activity of eravacycline against carbapenem-resistant enterobacteriaceae and Acinetobacter baumannii. Antimicrob Agents Chemother 60: 3840–3844
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wolff, M. De nouveaux antibiotiques : oui mais pour quelles situations en réanimation ?. Méd. Intensive Réa 26, 164–166 (2017). https://doi.org/10.1007/s13546-017-1272-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13546-017-1272-1